Business Wire·Mar 3, 2026, 8:30 AM ET

bioAffinity Technologies Presents Positive Research Findings for its Novel Diagnostic Platform Technology to Identify Optimal Therapies for Asthma Patients

bioAffinity Technologies, Inc. presented a scientific poster at the AAAAI 2026 Annual Meeting in Philadelphia on March 1.
The poster details the company's ability to identify drug antibody receptors in sputum for asthma therapies dupilumab & benralizumab.
Research presented by Chief Science Officer William Bauta, PhD aims to guide personalized treatment decisions & monitor inflammatory changes for asthma & COPD patients.
The technology utilizes a proprietary flow cytometry platform equipped with automated AI analysis to match patients with appropriate biologic therapies.
The company's existing commercial test, CyPath® Lung, is a noninvasive lung cancer diagnostic that demonstrated 92% sensitivity, 87% specificity, & 88% accuracy for small pulmonary nodules.
CyPath® Lung uses advanced flow cytometry & AI to identify malignancy-indicating cell populations in sputum via a fluorescent porphyrin.
CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies.
The press release includes standard forward-looking statements regarding risks related to regulatory approvals, clinical performance, & market acceptance.